MBM Wealth Consultants LLC Purchases 2,542 Shares of DexCom, Inc. $DXCM

MBM Wealth Consultants LLC increased its position in DexCom, Inc. (NASDAQ:DXCM) by 40.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,867 shares of the medical device company’s stock after purchasing an additional 2,542 shares during the period. MBM Wealth Consultants LLC’s holdings in DexCom were worth $774,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of DexCom by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock worth $4,218,063,000 after acquiring an additional 866,506 shares in the last quarter. Jennison Associates LLC grew its holdings in DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after purchasing an additional 994,300 shares during the period. Geode Capital Management LLC increased its stake in shares of DexCom by 3.4% during the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after purchasing an additional 358,617 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of DexCom in the 1st quarter worth approximately $554,893,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach acquired 18,200 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was bought at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the acquisition, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Alexander Collins sold 3,948 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $55.17, for a total value of $217,811.16. Following the completion of the transaction, the director directly owned 37,994 shares in the company, valued at approximately $2,096,128.98. This represents a 9.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 9,999 shares of company stock worth $619,391. Company insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. Argus lowered their price target on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Royal Bank Of Canada cut their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Wells Fargo & Company set a $93.00 price objective on shares of DexCom and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, The Goldman Sachs Group dropped their target price on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.73.

DexCom Price Performance

DXCM opened at $63.46 on Monday. The company’s 50-day simple moving average is $64.31 and its two-hundred day simple moving average is $75.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a market capitalization of $24.75 billion, a P/E ratio of 44.07, a P/E/G ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the previous year, the company earned $0.45 earnings per share. The firm’s quarterly revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.